CytoSorbents 公司宣布 CytoSorb® 獲得台灣監管部門批准

Core Insights - CytoSorbents Corporation has received approval from the Taiwan Food and Drug Administration (TFDA) for its CytoSorb product, which is designed for blood purification in critical care settings [1] - The company emphasizes the effectiveness of CytoSorb in managing cytokine storms associated with severe infections, including COVID-19, and aims to expand its market presence in Asia [1][2] - CytoSorb has been utilized in over 237,000 treatments globally, with a significant increase in demand noted during the COVID-19 pandemic [1][2] Company Overview - CytoSorbents Corporation specializes in blood purification technology, particularly through its flagship product, CytoSorb, which is used in intensive care units (ICUs) [1][2] - The company has established partnerships and collaborations with various healthcare organizations and government agencies to enhance its research and development efforts [2] Market Position - CytoSorbents is positioned to capitalize on the growing need for advanced blood purification solutions, especially in critical care environments [1][2] - The company has reported a 30% increase in revenue projections for the upcoming fiscal year, reflecting strong market demand and operational growth [1] Product Development - The company is actively involved in expanding its product line, including the development of new applications for CytoSorb and related technologies [2] - CytoSorb has received multiple regulatory approvals, including CE marking and FDA clearance, which supports its credibility and market access [2]